## **CLAIM AMENDMENTS**

## 1-21. (Canceled)

- 22. (Withdrawn Currently Amended) An isolated polypeptide selected from the group consisting of:
  - a) a polypeptide comprising an amino acid sequence of SEQ ID NO:1,
  - b) a polypeptide comprising a naturally occurring amino acid sequence at least 90% identical to an amino acid sequence of SEQ ID NO:1, and
  - an immunogenic portion of a polypeptide comprising consisting of the amino acid sequence of SEQ ID NO:1 selected from the group consisting of:
    - 1) an immunogenic portion of a polypeptide consisting of the sequence of SEQ ID NO:1 from residue 66 to residue 90;
    - 2 1) an immunogenic portion of a polypeptide consisting of the sequence of SEQ ID NO:1 from residue contiguous amino acid residues 120 to residue 141 of SEQ ID NO:1, and
    - 3 2) an immunogenic portion of a polypeptide consisting of the sequence
      of SEQ ID NO:1 from residue contiguous amino acid residues 234 to residue 245
      of SEQ ID NO:1, and
    - 4) an immunogenic portion of a polypeptide consisting of the sequence of SEQ ID NO:1 from residue 351 to residue 359.
- 23. (Withdrawn) An isolated polypeptide of claim 22 comprising an amino acid sequence of SEQ ID NO:1.
- 24. (Currently Amended) An isolated polynucleotide encoding a polypeptide of claim 22 selected from the group consisting of:
  - a) a polypeptide comprising an amino acid sequence of SEQ ID NO:1,
  - b) a polypeptide comprising a naturally occurring amino acid sequence at least 90% identical to an amino acid sequence of SEQ ID NO:1, and

an immunogenic portion of a polypeptide consisting of the amino acid sequence of SEQ
 ID NO:1 selected from the group consisting of:

- i) an immunogenic portion consisting of contiguous amino acid residues 120 to 141 of SEQ ID NO:1, and
- ii) an immunogenic portion consisting of contiguous amino acid residues 234 to 245 of SEQ ID NO:1.
- 25. (Currently Amended) An isolated polynucleotide encoding a polypeptide of claim 23 comprising an amino acid sequence of SEQ ID NO:1.
- 26. (Previously Presented) An isolated polynucleotide of claim 25 comprising a polynucleotide sequence of SEQ ID NO:3.
- 27. (Previously Presented) A recombinant polynucleotide comprising a promoter sequence operably linked to a polynucleotide of claim 24.
  - 28. (Previously Presented) A cell transformed with a recombinant polynucleotide of claim 27.
  - 29. (Withdrawn) A method of producing a polypeptide of claim 22, the method comprising:
  - a) culturing a cell under conditions suitable for expression of the polypeptide, wherein said cell is transformed with a recombinant polynucleotide, and said recombinant polynucleotide comprises a promoter sequence operably linked to a polynucleotide encoding the polypeptide of claim 22, and
  - b) recovering the polypeptide so expressed.
- 30. (Withdrawn) A method of claim 29, wherein the polypeptide comprises an amino acid sequence of SEQ ID NO:1.
  - 31. (Previously Presented) An isolated polynucleotide selected from the group consisting of:
  - a) a polynucleotide comprising a polynucleotide sequence of SEQ ID NO:3.

- b) a polynucleotide comprising a naturally occurring polynucleotide sequence at least 90% identical to a polynucleotide sequence of SEQ ID NO:3,
- c) a polynucleotide complementary to a polynucleotide of a),
- d) a polynucleotide complementary to a polynucleotide of b). and
- e) an RNA equivalent of a)-d).
- 32. (Withdrawn) A method of detecting a target polynucleotide in a sample, said target polynucleotide having a sequence of a polynucleotide of claim 31, the method comprising:
  - a) hybridizing the sample with a probe comprising at least 20 contiguous nucleotides comprising a sequence complementary to said target polynucleotide in the sample, and which probe specifically hybridizes to said target polynucleotide, under conditions whereby a hybridization complex is formed between said probe and said target polynucleotide or fragments thereof, and
  - b) detecting the presence or absence of said hybridization complex, and, optionally, if present, the amount thereof.
- 33. (Withdrawn) A method of claim 32, wherein the probe comprises at least 60 contiguous nucleotides.
- 34. (Withdrawn) A method of detecting a target polynucleotide in a sample, said target polynucleotide having a sequence of a polynucleotide of claim 31, the method comprising:
  - a) amplifying said target polynucleotide or fragment thereof using polymerase chain reaction amplification, and
  - b) detecting the presence or absence of said amplified target polynucleotide or fragment thereof, and, optionally, if present, the amount thereof.
- 35. (Withdrawn) A method of screening a compound for effectiveness in altering expression of a target polynucleotide, wherein said target polynucleotide comprises a sequence of claim 26, the method comprising:
  - a) exposing a sample comprising the target polynucleotide to a compound, under conditions suitable for the expression of the target polynucleotide,

- b) detecting altered expression of the target polynucleotide, and
- c) comparing the expression of the target polynucleotide in the presence of varying amounts of the compound and in the absence of the compound.
- 36. (Withdrawn) A method of assessing toxicity of a test compound, the method comprising:
- a) treating a biological sample containing nucleic acids with the test compound.
- b) hybridizing the nucleic acids of the treated biological sample with a probe comprising at least 20 contiguous nucleotides of a polynucleotide of claim 31 under conditions whereby a specific hybridization complex is formed between said probe and a target polynucleotide in the biological sample, said target polynucleotide comprising a polynucleotide sequence of a polynucleotide of claim 31 or fragment thereof,
- c) quantifying the amount of hybridization complex, and
- d) comparing the amount of hybridization complex in the treated biological sample with the amount of hybridization complex in an untreated biological sample, wherein a difference in the amount of hybridization complex in the treated biological sample is indicative of toxicity of the test compound.
- 37. (Currently Amended) A fragment of a polynucleotide comprising the sequence of SEQ ID NO:3 selected from the group consisting of:
  - a) a fragment of a polynucleotide consisting of the sequence of SEQ ID NO:3 from nucleotide 170 to nucleotide 220, and
  - b) a fragment of a polynucleotide consisting of the sequence of SEQ ID NO:3 from nucleotide 1015 to nucleotide 1055.